S&P 500   3,351.28 (+0.06%)
DOW   27,433.48 (+0.17%)
QQQ   271.47 (-1.15%)
AAPL   444.45 (-2.45%)
MSFT   212.48 (-1.79%)
FB   268.44 (+1.19%)
GOOGL   1,498.37 (-0.44%)
AMZN   3,163.92 (-1.89%)
NVDA   447.98 (-1.20%)
CGC   16.63 (-5.08%)
BABA   252.10 (-5.11%)
TSLA   1,453.61 (-2.41%)
MU   48.75 (+0.10%)
GE   6.40 (+1.11%)
AMD   84.85 (-2.15%)
T   30.02 (+0.60%)
F   6.86 (-1.01%)
ACB   10.27 (-0.39%)
GILD   69.35 (+0.78%)
NFLX   494.73 (-2.82%)
DIS   129.93 (-0.68%)
BAC   26.11 (+2.51%)
BA   170.02 (-1.27%)
S&P 500   3,351.28 (+0.06%)
DOW   27,433.48 (+0.17%)
QQQ   271.47 (-1.15%)
AAPL   444.45 (-2.45%)
MSFT   212.48 (-1.79%)
FB   268.44 (+1.19%)
GOOGL   1,498.37 (-0.44%)
AMZN   3,163.92 (-1.89%)
NVDA   447.98 (-1.20%)
CGC   16.63 (-5.08%)
BABA   252.10 (-5.11%)
TSLA   1,453.61 (-2.41%)
MU   48.75 (+0.10%)
GE   6.40 (+1.11%)
AMD   84.85 (-2.15%)
T   30.02 (+0.60%)
F   6.86 (-1.01%)
ACB   10.27 (-0.39%)
GILD   69.35 (+0.78%)
NFLX   494.73 (-2.82%)
DIS   129.93 (-0.68%)
BAC   26.11 (+2.51%)
BA   170.02 (-1.27%)
S&P 500   3,351.28 (+0.06%)
DOW   27,433.48 (+0.17%)
QQQ   271.47 (-1.15%)
AAPL   444.45 (-2.45%)
MSFT   212.48 (-1.79%)
FB   268.44 (+1.19%)
GOOGL   1,498.37 (-0.44%)
AMZN   3,163.92 (-1.89%)
NVDA   447.98 (-1.20%)
CGC   16.63 (-5.08%)
BABA   252.10 (-5.11%)
TSLA   1,453.61 (-2.41%)
MU   48.75 (+0.10%)
GE   6.40 (+1.11%)
AMD   84.85 (-2.15%)
T   30.02 (+0.60%)
F   6.86 (-1.01%)
ACB   10.27 (-0.39%)
GILD   69.35 (+0.78%)
NFLX   494.73 (-2.82%)
DIS   129.93 (-0.68%)
BAC   26.11 (+2.51%)
BA   170.02 (-1.27%)
S&P 500   3,351.28 (+0.06%)
DOW   27,433.48 (+0.17%)
QQQ   271.47 (-1.15%)
AAPL   444.45 (-2.45%)
MSFT   212.48 (-1.79%)
FB   268.44 (+1.19%)
GOOGL   1,498.37 (-0.44%)
AMZN   3,163.92 (-1.89%)
NVDA   447.98 (-1.20%)
CGC   16.63 (-5.08%)
BABA   252.10 (-5.11%)
TSLA   1,453.61 (-2.41%)
MU   48.75 (+0.10%)
GE   6.40 (+1.11%)
AMD   84.85 (-2.15%)
T   30.02 (+0.60%)
F   6.86 (-1.01%)
ACB   10.27 (-0.39%)
GILD   69.35 (+0.78%)
NFLX   494.73 (-2.82%)
DIS   129.93 (-0.68%)
BAC   26.11 (+2.51%)
BA   170.02 (-1.27%)
Log in

NASDAQ:EYPTEyepoint Pharmaceuticals Stock Price, Forecast & News

$0.70
+0.03 (+4.48 %)
(As of 08/7/2020 04:00 PM ET)
Add
Compare
Today's Range
$0.65
Now: $0.70
$0.72
50-Day Range
$0.69
MA: $0.76
$0.89
52-Week Range
$0.65
Now: $0.70
$2.69
Volume845,669 shs
Average Volume786,332 shs
Market Capitalization$87.32 million
P/E RatioN/A
Dividend YieldN/A
Beta1.29
EyePoint Pharmaceuticals, Inc., a specialty biopharmaceutical company, develops and commercializes ophthalmic products for the treatment of eye diseases in the United States and Europe. It provides ILUVIEN for the treatment of diabetic macular edema; YUTIQ, a non-erodible fluocinolone acetonide insert for the treatment of non-infectious posterior uveitis (NIPU) that is in the Phase III clinical trials; and Retisert (fluocinolone acetonide intravitreal implant), a sustained-release implant for the treatment of posterior segment uveitis. The company also offers DEXYCU (dexamethasone intraocular suspension), an intraocular product for the treatment of postoperative ocular inflammation; and Vitrasert (ganciclovir), a sustained release implant for the treatment of cytomegalovirus retinitis. In addition, it develops YUTIQ shorter-acting uveitis for the treatment of NIPU; and Durasert tyrosine kinase inhibitor for the treatment of wet age-related macular degeneration. Further, the company's development program focuses on developing sustained release products using its Durasert and Verisome technology platforms to deliver drugs to treat chronic diseases. It has strategic collaborations with Alimera Sciences, Inc., Bausch & Lomb, OncoSil Medical UK Limited, and Ocumension Therapeutics. The company was formerly known as pSivida Corp. and changed its name to EyePoint Pharmaceuticals, Inc. in March 2018. EyePoint Pharmaceuticals, Inc. was founded in 1987 and is headquartered in Watertown, Massachusetts.
Read More
Eyepoint Pharmaceuticals logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.3Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 2.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.72 out of 5 stars


Industry, Sector and Symbol

Industry Analytical instruments
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:EYPT
CUSIPN/A
Phone617-926-5000

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$20.36 million
Book Value$0.08 per share

Profitability

Net Income$-56,790,000.00
Net Margins-229.34%

Miscellaneous

Employees55
Market Cap$87.32 million
Next Earnings Date11/5/2020 (Estimated)
OptionableOptionable
$0.70
+0.03 (+4.48 %)
(As of 08/7/2020 04:00 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive EYPT News and Ratings via Email

Sign-up to receive the latest news and ratings for EYPT and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Eyepoint Pharmaceuticals (NASDAQ:EYPT) Frequently Asked Questions

How has Eyepoint Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)?

Eyepoint Pharmaceuticals' stock was trading at $1.05 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, EYPT shares have decreased by 32.4% and is now trading at $0.71.
View which stocks have been most impacted by Coronavirus
.

Do Wall Street analysts recommend investors buy shares of Eyepoint Pharmaceuticals?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Eyepoint Pharmaceuticals in the last year. There are currently 2 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Eyepoint Pharmaceuticals
.

When is Eyepoint Pharmaceuticals' next earnings date?

Eyepoint Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, November 5th 2020.
View our earnings forecast for Eyepoint Pharmaceuticals
.

How were Eyepoint Pharmaceuticals' earnings last quarter?

Eyepoint Pharmaceuticals Inc (NASDAQ:EYPT) posted its quarterly earnings results on Wednesday, August, 5th. The company reported ($0.10) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.11) by $0.01. Eyepoint Pharmaceuticals had a negative return on equity of 374.22% and a negative net margin of 229.34%.
View Eyepoint Pharmaceuticals' earnings history
.

What price target have analysts set for EYPT?

4 Wall Street analysts have issued 1 year target prices for Eyepoint Pharmaceuticals' stock. Their forecasts range from $1.00 to $5.00. On average, they anticipate Eyepoint Pharmaceuticals' share price to reach $3.63 in the next twelve months. This suggests a possible upside of 410.6% from the stock's current price.
View analysts' price targets for Eyepoint Pharmaceuticals
.

Has Eyepoint Pharmaceuticals been receiving favorable news coverage?

News coverage about EYPT stock has been trending positive recently, according to InfoTrie Sentiment. InfoTrie identifies positive and negative media coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Eyepoint Pharmaceuticals earned a daily sentiment score of 2.1 on InfoTrie's scale. They also gave media stories about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the stock's share price in the next few days.
View the latest news about Eyepoint Pharmaceuticals
.

Are investors shorting Eyepoint Pharmaceuticals?

Eyepoint Pharmaceuticals saw a decline in short interest during the month of July. As of July 31st, there was short interest totaling 2,180,000 shares, a decline of 18.7% from the July 15th total of 2,680,000 shares. Based on an average daily trading volume, of 854,200 shares, the days-to-cover ratio is currently 2.6 days. Currently, 2.7% of the shares of the company are short sold.
View Eyepoint Pharmaceuticals' Current Options Chain
.

Who are some of Eyepoint Pharmaceuticals' key competitors?

What other stocks do shareholders of Eyepoint Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Eyepoint Pharmaceuticals investors own include Sorrento Therapeutics (SRNE), XOMA (XOMA), Amarin (AMRN), Opko Health (OPK), Progenics Pharmaceuticals (PGNX), Verastem (VSTM), AcelRx Pharmaceuticals (ACRX), Inovio Pharmaceuticals (INO), Catalyst Pharmaceuticals (CPRX) and Exelixis (EXEL).

Who are Eyepoint Pharmaceuticals' key executives?

Eyepoint Pharmaceuticals' management team includes the following people:
  • Ms. Nancy S. Lurker, Pres, CEO & Director (Age 62)
  • Mr. Leonard S. Ross, VP of Fin. & Chief Accounting Officer (Age 69)
  • Dr. Dario A. Paggiarino, VP & Chief Medical Officer (Age 62)
  • Mr. David J. Price, Chief Financial Officer (Age 56)
  • Mr. Marty Nazzaro, Sr. VP of Operations

What is Eyepoint Pharmaceuticals' stock symbol?

Eyepoint Pharmaceuticals trades on the NASDAQ under the ticker symbol "EYPT."

Who are Eyepoint Pharmaceuticals' major shareholders?

Eyepoint Pharmaceuticals' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include UBS Group AG (0.09%), Endurance Wealth Management Inc. (0.03%) and Principal Financial Group Inc. (0.03%). Company insiders that own Eyepoint Pharmaceuticals stock include Douglas Evan Godshall, George Elston, Jay S Duker, John B Landis and Nancy Lurker.
View institutional ownership trends for Eyepoint Pharmaceuticals
.

Which institutional investors are buying Eyepoint Pharmaceuticals stock?

EYPT stock was purchased by a variety of institutional investors in the last quarter, including UBS Group AG, Principal Financial Group Inc., and Endurance Wealth Management Inc.. Company insiders that have bought Eyepoint Pharmaceuticals stock in the last two years include Douglas Evan Godshall, George Elston, Jay S Duker, John B Landis, and Nancy Lurker.
View insider buying and selling activity for Eyepoint Pharmaceuticals
.

How do I buy shares of Eyepoint Pharmaceuticals?

Shares of EYPT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Eyepoint Pharmaceuticals' stock price today?

One share of EYPT stock can currently be purchased for approximately $0.71.

How big of a company is Eyepoint Pharmaceuticals?

Eyepoint Pharmaceuticals has a market capitalization of $88.57 million and generates $20.36 million in revenue each year. The company earns $-56,790,000.00 in net income (profit) each year or ($0.48) on an earnings per share basis. Eyepoint Pharmaceuticals employs 55 workers across the globe.

What is Eyepoint Pharmaceuticals' official website?

The official website for Eyepoint Pharmaceuticals is www.eyepointpharma.com.

How can I contact Eyepoint Pharmaceuticals?

Eyepoint Pharmaceuticals' mailing address is 480 PLEASANT STREET SUITE B300, WATERTOWN MA, 02472. The company can be reached via phone at 617-926-5000 or via email at [email protected]

This page was last updated on 8/7/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.